Rapid antigen tests for COVID-19 screening in children do not meet WHO, FDA standards: BMJ
UK: Rapid antigen tests (also called lateral flow tests) are used widely for screening COVID-19 in children. A recent meta-analysis published in the journal BMJ Evidence-Based Medicine has revealed that COVID-19 rapid antigen tests for children do not meet minimum performance standards set by the US Food and Drug Administration (FDA) and World Health Organization (WHO). Therefore, high false-negative results limit their value in children for the diagnosis of COVID-19 infection.
"The performance of current antigen tests in children under real-life conditions varies broadly. Related data were identified only for very few antigen tests on the market, and owing to poor reporting, the risk of bias was mostly unclear," Naomi Fujita-Rohwerder, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK, and colleagues wrote in their study.
Also, the most common uses of these tests in children (eg, self-testing in schools or parents testing their toddlers before kindergarten) have not yet been addressed in clinical performance studies, they explained. The observed low diagnostic sensitivity may affect the planned purpose of the broad implementation of testing programs, they wrote.
In schools and kindergarten, antigen tests are used widely for detecting children with current SARS-CoV-2 infection despite an ongoing debate on potential benefits and harms. In adult populations, sensitivity estimates of antigen test vary broadly and are substantially lower than reported by manufacturers; however, test performance in pediatric populations remained unknown.
Against the above background, Dr. Fujita-Rohwerder and colleagues aimed to systematically assess the diagnostic accuracy of rapid point-of-care tests for the diagnosis of current SARS-CoV-2 infections in children under real-life conditions. For this purpose, they searched the online databases from 1 January 2020 to 24 May 2021.
Diagnostic cross-sectional or cohort studies having pediatric study participants and compared rapid point-of-care tests for diagnosing current SARS-CoV-2 infections with reverse transcription-polymerase chain reaction (RT-PCR) as the reference standard were included. The risk of bias and the applicability of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool.
17 studies with a total of 6355 pediatric study participants were included. All studies compared antigen tests against RT-PCR. Overall, studies evaluated eight antigen tests from six different brands. Only one study was at low risk of bias.
The study revealed the following findings:
- The pooled overall diagnostic sensitivity and specificity in pediatric populations were 64.2% and 99.1%, respectively.
- In symptomatic children, the pooled diagnostic sensitivity was 71.8% and the pooled diagnostic specificity was 98.7%.
- The pooled diagnostic sensitivity in asymptomatic children was 56.2% and the pooled diagnostic specificity was 98.6%.
"The observed low diagnostic sensitivity may impact the intended purpose of antigen tests in children," wrote the authors. In this systematic review, evidence gaps demonstrate current research needs to support evidence-based decision making."
"In particular, evidence is needed on the real-life performance of tests in schools (self-testing performed by children) and kindergarten (sample collection in toddlers by laypersons)," they concluded.
Reference:
Fujita-Rohwerder N, Beckmann L, Zens Y, et alDiagnostic accuracy of rapid point-of-care tests for diagnosis of current SARS-CoV-2 infections in children: a systematic review and meta-analysis BMJ Evidence-Based Medicine Published Online First: 18 January 2022. doi: 10.1136/bmjebm-2021-111828
